Von Willebrand Disease (VWD) is a rare inherited bleeding disorder caused by a deficiency or defect in the von Willebrand factor (VWF), a protein that helps the blood to clot. It is the most common inherited bleeding disorder, affecting both males and females. Symptoms of VWD can range from mild to severe, and include prolonged bleeding from cuts, nosebleeds, and heavy menstrual bleeding. Treatment for VWD typically involves the use of desmopressin, a synthetic form of the hormone vasopressin, and/or replacement therapy with VWF concentrates. The VWD market is a subset of the larger hematology market, which includes treatments for a variety of blood-related disorders. The VWD market is expected to grow due to increasing awareness of the disorder, as well as the development of new treatments. Companies in the VWD market include Shire, CSL Behring, Octapharma, Grifols, and Kedrion. Show Less Read more
ASK A QUESTION
We request your telephone number so we can contact you in the event we have difficulty reaching you via email. We aim to respond to all questions on the same business day.
